Wound healing after excision of subcutaneous tumors treated with near-infrared photoimmunotherapy.


Journal

Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310

Informations de publication

Date de publication:
08 2020
Historique:
received: 22 05 2020
accepted: 02 06 2020
pubmed: 25 6 2020
medline: 5 6 2021
entrez: 25 6 2020
Statut: ppublish

Résumé

Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer therapy that employs a combination of infrared light and tumor-targeted monoclonal antibody-photoabsorber conjugates to cause both direct tumor necrosis and immunogenic cell death. NIR-PIT may have potential in the perioperative setting before surgery, and therefore it is important to know the effect of NIR-PIT on wound healing. Fifty mice were implanted with subcutaneous xenografts of N87 human gastric cancer cells, and tumors were excised after reaching a predetermined size. After excision, 30 mice were split into three groups: Controls, NIR-PIT 1 day prior to surgery and NIR-PIT 3 days prior to surgery. The quantity of reactive oxygen species (ROS) in each wound was measured on Postoperative Days 2 and 4, and mice were monitored weekly for 4 weeks for evidence of local tumor recurrence as well as clinical evidence of wound healing complications (eg, dehiscence, infection). The remaining 20 mice (10 controls, 10 treated with NIR-PIT 1 day prior to surgery) were sacrificed on either Postoperative Day 7 or 14, the skin around wounds were excised, and tensile strength was measured with a digital force gauge. There were no significant differences between treatment and control groups with respect to wound ROS levels, wound tensile strength, local tumor recurrence, or postoperative complication rates (P > .05). In conclusion, neoadjuvant (pre-operative) NIR-PIT shows no evidence of adverse wound healing effects, and it is likely a safe adjunctive treatment to surgery. Postoperative use of NIR-PIT merits investigation.

Identifiants

pubmed: 32579795
doi: 10.1002/cam4.3247
pmc: PMC7433815
doi:

Substances chimiques

Reactive Oxygen Species 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5932-5939

Subventions

Organisme : Intramural NIH HHS
ID : ZIA BC011513
Pays : United States

Informations de copyright

© Published 2020. This article is a U.S. Government work and is in the public domain in the USA. Cancer Medicine published by John Wiley & Sons Ltd.

Références

Biomaterials. 2011 Mar;32(7):1796-801
pubmed: 21146868
Free Radic Biol Med. 2013 Dec;65:1310-1314
pubmed: 24080119
Cancer Med. 2020 Aug;9(16):5932-5939
pubmed: 32579795
Br J Cancer. 1999 Mar;79(9-10):1392-8
pubmed: 10188881
MethodsX. 2018 Apr 16;5:337-344
pubmed: 30050753
Nat Med. 2011 Nov 06;17(12):1685-91
pubmed: 22057348
J Invest Dermatol. 2011 Feb;131(2):518-28
pubmed: 20927125
Cancer Res. 1994 Aug 15;54(16):4334-41
pubmed: 7519120
Ann Surg. 1975 Jun;181(6):842-6
pubmed: 1138634
Am J Surg. 2004 May;187(5A):11S-16S
pubmed: 15147986
Crit Rev Oncol Hematol. 2014 Jan;89(1):16-26
pubmed: 23958676
Clin Dermatol. 2007 Jan-Feb;25(1):9-18
pubmed: 17276196
J Biomed Biotechnol. 2011;2011:969618
pubmed: 21151647
J Vis Exp. 2018 Nov 17;(141):
pubmed: 30507922
Int Wound J. 2017 Feb;14(1):89-96
pubmed: 26688157
J Trauma. 1994 Jun;36(6):810-3; discussion 813-4
pubmed: 8015002
J Invest Dermatol. 2001 Jul;117(1):3-15
pubmed: 11442744
Wound Repair Regen. 2000 Mar-Apr;8(2):83-96
pubmed: 10810034
Wound Repair Regen. 1998 Mar-Apr;6(2):127-34
pubmed: 9776855
Br J Surg. 1998 Apr;85(4):444-60
pubmed: 9607524
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Cancer Med. 2016 Jul;5(7):1526-34
pubmed: 27167827
Lasers Med Sci. 2010 Sep;25(5):761-6
pubmed: 20496092
Photomed Laser Surg. 2005 Oct;23(5):485-92
pubmed: 16262579
Clin Cancer Res. 2019 Jun 15;25(12):3561-3571
pubmed: 30890547
Cancer Immunol Res. 2019 Mar;7(3):401-413
pubmed: 30683733
Clin Dermatol. 2007 Jan-Feb;25(1):19-25
pubmed: 17276197
Eur Cell Mater. 2012 Sep 24;24:249-65
pubmed: 23007910
J Surg Res. 2015 Jul;197(1):5-11
pubmed: 25799527
Cancer Immunol Res. 2020 Mar;8(3):345-355
pubmed: 31953245
Lasers Med Sci. 2016 Nov;31(8):1683-1689
pubmed: 27495128
Oncotarget. 2017 Feb 7;8(6):10425-10436
pubmed: 28060726
Eur Surg Res. 2009;43(1):61-5
pubmed: 19451720
Wound Repair Regen. 2016 Jan-Feb;24(1):26-34
pubmed: 26562746
Mol Pharm. 2017 Dec 4;14(12):4628-4635
pubmed: 29135265
Acc Chem Res. 2019 Aug 20;52(8):2332-2339
pubmed: 31335117
Gastric Cancer. 2019 May;22(3):463-472
pubmed: 30171392

Auteurs

Adrian Rosenberg (A)

Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Fuyuki Inagaki (F)

Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Takuya Kato (T)

Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Ryuhei Okada (R)

Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Hiroaki Wakiyama (H)

Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Aki Furusawa (A)

Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Peter L Choyke (PL)

Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Hisataka Kobayashi (H)

Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH